|Bid||20.46 x 800|
|Ask||20.49 x 1000|
|Day's Range||20.39 - 20.58|
|52 Week Range||17.60 - 21.45|
|Beta (3Y Monthly)||-0.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.25|
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Aug. 30.) Inspire Medical Systems Inc (NYSE: INSP ...
FDA activity remained brisk in August. The FDA gave its nod for a majority of drugs that came up for review, although Vanda Pharmaceuticals Inc. (NASDAQ: VNDA )'s jet lag disorder drug Hetlioz and Sarepta ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 14) GENMAB A/S/S ADR (NASDAQ: GMAB ) (announced first-half ...
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Douyu International Holdings Ltd (DOYU) will issue nearly 67.4 million ...
International bio-tech company Genmab is on a mission to improve the life of cancer patients, after becoming the second largest U.S. IPO ever by a bio-tech company. Genmab CEO Jan van de Winkel joins Yahoo Finance's Adam Shapiro and Julie Hyman to discuss.